Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008 Mar;50(3):679-80

Date

08/11/2006

Pubmed ID

16900484

DOI

10.1002/pbc.21009

Scopus ID

2-s2.0-38549143161   17 Citations

Abstract

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Author List

Burke MJ, Cohn SL

Author

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adrenal Cortex Hormones
Adrenal Gland Neoplasms
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Child Behavior Disorders
Child, Preschool
Combined Modality Therapy
Diagnostic Errors
Ganglioneuroblastoma
Humans
Immunoglobulins, Intravenous
Immunosuppressive Agents
Immunotherapy
Male
Opsoclonus-Myoclonus Syndrome
Psychomotor Disorders
Recurrence
Rituximab
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a